摘要
目的:探讨联合应用多奈哌齐和艾地苯醌治疗高龄血管性痴呆(VaD)疗效及安全性。方法:收集60例VaD患者,随机分为对照组和治疗组,对照组给予盐酸多奈哌齐药物(5mg,1次/d)治疗24周,治疗组在此基础上加用艾地苯醌(30mg/次,每日3次)治疗24周,治疗前、治疗后12周及24周分别进行MMSE、ADAS-Cog及ADAS-ADL量表测评,从而评估药物疗效,同时治疗前及治疗后24周完善血尿便常规、肝肾功能、叶酸、维生素B12、甲状腺功能、心电图等评估药物的安全性。结果:两组在治疗12周后MMSE、ADAS-Cog及ADAS-ADL量表评分与治疗前比较,差异无统计学意义(P>0.05),在治疗24周后,对照组和治疗组MMSE评分和治疗前比较,差异没有统计学意义(P>0.05),而ADAS-Cog及ADAS-ADL量表评分和治疗前比较,差异有统计学意义(P<0.01),且2组间比较差异有统计学意义(P<0.05)。结论:联合应用多奈哌齐和艾地苯醌治疗高龄血管性痴呆24周后在一定程度上改善患者的认知功能及日常生活能力,而且联合治疗较单独应用多奈哌齐疗效更好,且在治疗周期内未出现明显不良反应。
Objective:To investigate the efficacy and safety of donepezil and idebenone on the treatment of senile vascular dementia( VaD).Methods:60 patients with VaD were randomly divided into control group and treatment group.Control group were given drug donepezil( 5 mg,one time a day) for 24 weeks,based on which the treatment group idebenone( 30 mg/time,three times a day) for 24 weeks.In the 12 th and 24 th weeks before and after treatment,drug efficacy was measured with MMSE,ADAS-Cog and ADAS-ADL.At the same time,the safety of the drugs was evaluated for the blood、urinalysis and stool routine,liver and kidney function,folicacid,vitamin B12,thyroid function,electrocardiogram before and after 24 weeks treatment.Results:Scale scores of MMSE,ADAS Cog and ADAS-ADL in two groups had no statistically significant difference( P > 0.05) after 12 weeks of treatment compared with those before treatment.After 24 weeks of treatment,the difference of MMSE scores in the control group and treatment group had no statistical significance( P > 0.05) compared with that before treatment.The difference on the scale scores of ADAS-Cog and ADAS-ADL was statistically significant( P < 0.01) compared with that before treatment.The differences between the two groups were statistically significant( P < 0.05).Conclusions:The application of donepezil and idebenone on the treatment of senile vascular dementia for 24 weeks could improve patients' cognitive function and daily life ability in certain degree.Combined application could have a better efficacy compared with separate usage.No obvious adverse reaction appears during the treatment.
出处
《黑龙江医药科学》
2018年第1期49-51,45,共4页
Heilongjiang Medicine and Pharmacy
基金
南京医科大学科技发展基金重点项目
编号:2014NJMUZD059
